Infusion Adriamycin and Radiation in Hepatomas

  • Richard S. Stark
  • C. Julian Rosenthal
  • Marvin Rotman
Part of the Medical Radiology book series (MEDRAD)


Hepatocellular carcinoma is a highly malignant tumor with a median survival time of only 4 months from the onset of symptoms and 2 months from the diagnosis (Nagasue et al. 1984; Falkson and Coetzer 1986). While radiation has some activity, its effectiveness is limited by the liver tolerance (zum Winkel et al. 1986). Cytotoxic chemotherapy has usually produced disappointing results (Falkson and Coetzer 1986). New approaches are needed for the treatment of this disease. One such new approach is the concomitant use of hepatic radiation and chemotherapy. The optimal chemotherapy would be drugs which are both individually active in the treatment of hepatocellular carcinoma as well as having a potential for radiation sensitization.


Response Duration Intrahepatic Cholestasis Hepatocellular Cancer Metastatic Liver Cancer Radiation Therapy Oncology Group Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Doci R, Bignami P, Bozzetti A, Bonfanti G, Audisio R, Colombo M, Gennari L (1988) Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 61: 1983–1987PubMedCrossRefGoogle Scholar
  2. Falkson G, Coetzer BJ (1986) Application and results of different chemotherapy regimens in primary liver malignancies. In: Herfarth C, Schlag P, Hohenberger P (eds) Therapeutic strategies in primary and metastatic liver cancer. Springer, Berlin Heidelberg New York (Recent Results in Cancer Research, vol 100, pp 103–111)CrossRefGoogle Scholar
  3. Friedman MA, Volberding PA, Cassidy MJ, Resser KJ, Wasserman TH, Philips TL (1979) Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole liver radiation: an NCOG study. Cancer Treat Rep 63: 1885–1888PubMedGoogle Scholar
  4. Ihde DC, Kane RH, Cohen MH, Mclntyre KR, Minna JD (1977) Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 61: 1385–1387PubMedGoogle Scholar
  5. Kun LE, Camitta BM (1978) Hepatopathy following irradiation and adriamycin. Cancer 42: 81–84PubMedCrossRefGoogle Scholar
  6. Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma, a study of 100 untreated cases. Cancer 54: 1461–1465PubMedCrossRefGoogle Scholar
  7. Ohnishi K, Sugita S, Nomura F, Iida S, Tanabe Y (1987) Arterial chemoembolization with mitomycin microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma. Am J Gastroenterol 82: 876–879PubMedGoogle Scholar
  8. Olweny CL, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK (1980) Further experience in treating hepatocellular carcinoma in Uganda. Cancer 46: 2717–2722PubMedCrossRefGoogle Scholar
  9. Order SE, Stillwagon GB, Klein JL et al. (1985) Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol 3: 1573–1582PubMedGoogle Scholar
  10. Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit GM (1988) Hepatocellular carcinoma-a retrospective analysis of treatments to manage disease confined to the liver. Cancer 61: 1887–1888CrossRefGoogle Scholar
  11. Rosenthal CJ, Rotman M, Bhutiani I (1986) Concomitant radiation therapy and doxorubicin by continuous infusion in advanced malignancies - a phase I-II study - evidence of synergistic effect in soft tissue sarcomas and hepatomas. In: Rosenthal CJ, Rotman M (eds) Clinical applications of continuous infusion chemotherapy and concomitant radiation therapy. Plenum, New York, pp 159–175CrossRefGoogle Scholar
  12. Sasaki Y, Imaoka S, Kasugai H et al. (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60: 1194–1203PubMedCrossRefGoogle Scholar
  13. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L (1985) Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 56: 2751–2755PubMedCrossRefGoogle Scholar
  14. Vogel CL, Bayley AC, Brooker RJ, Anthony PP, Ziegler JL (1977) A phase II study of adriamycin (NSC 123 127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39: 1923–1929PubMedCrossRefGoogle Scholar
  15. Zum Winkel K, Wieland C, Weischedel N (1986) Therapeutic strategies in primary and metastatic liver cancer: indication and results of external radiation therapy. In: Herfarth C, Schlag P, Hohenberger P (eds) Therapeutic strategies in primary and metastatic liver cancer. Springer, Berlin Heidelberg New York (Recent Results in Cancer Research, vol 100, pp 289–297)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Richard S. Stark
    • 1
  • C. Julian Rosenthal
    • 2
  • Marvin Rotman
    • 2
  1. 1.Interfaith Medical CenterBrooklynUSA
  2. 2.Department of Radiation OncologySUNY Health Science Center at BrooklynBrooklynUSA

Personalised recommendations